Get the Stockscreener App
11.90
1.71%
0.23
Gyre Therapeutics Inc stock is traded at $11.90, with a volume of 23,297.
It is up +1.71% in the last 24 hours and up +0.76% over the past month.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
See More
Previous Close:
$11.67
Open:
$11.61
24h Volume:
23,297
Relative Volume:
0.23
Market Cap:
$1.02B
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
127.27
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
+10.93%
1M Performance:
+0.76%
6M Performance:
-12.14%
1Y Performance:
-37.56%
1-Day Range:
$11.61
$12.03
1-Week Range:
$9.1421
$13.75
52-Week Range:
$8.26
$19.96
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(619) 949-3681
Address
12770 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
11.85 | 1.02B | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.75 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.31 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
579.80 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.16 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.04 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Exploring High Growth Tech Stocks In The US March 2025 - Simply Wall St
Gyre Therapeutics (NASDAQ:GYRE) Coverage Initiated by Analysts at Noble Financial - Defense World
Gyre therapeutics president Ma Songjiang sells $40,776 in stock - Investing.com
Noble Capital Initiates Coverage on Gyre Therapeutics With Outperform Rating, $20 Price Target - Marketscreener.com
Gyre Therapeutics initiated with an Outperform at Noble Capital - TipRanks
Gyre Therapeutics president Ma Songjiang sells $42,480 in stock - MSN
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up – Still a Buy? - Defense World
Gyre Therapeutics president Ma Songjiang sells $43,560 in stock - Investing.com India
Gyre Therapeutics president Ma Songjiang sells $43,560 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics president Ma Songjiang sells $44,180 in stock - Investing.com
Contrasting IGM Biosciences (NASDAQ:IGMS) and Gyre Therapeutics (NASDAQ:GYRE) - Defense World
Gyre Therapeutics president Ma Songjiang sells $45,480 in stock By Investing.com - Investing.com South Africa
Gyre Therapeutics president Ma Songjiang sells $45,480 in stock - Investing.com India
Public companies in Gyre Therapeutics, Inc. (NASDAQ:GYRE) are its biggest bettors, and their bets paid off as stock gained 10.0% last week - Simply Wall St
Gyre Therapeutics president Ma Songjiang sells shares for $42,860 - MSN
Gyre Therapeutics (NASDAQ:GYRE) Trading 7.6% HigherShould You Buy? - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 9.1%What's Next? - MarketBeat
Gyre Therapeutics president Ma Songjiang sells $49,380 in stock By Investing.com - Investing.com Australia
Gyre Therapeutics president Ma Songjiang sells $49,380 in stock - Investing.com
Gyre Therapeutics Faces Revenue Decline Amidst Future Prospects - TipRanks
Gyre therapeutics president Ma Songjiang sells $46,360 in stock - MSN
Gyre therapeutics president Ma Songjiang sells $45,434 in stock - MSN
Gyre therapeutics president Ma Songjiang sells $46,360 in stock By Investing.com - Investing.com Nigeria
Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 2,000 Shares - MarketBeat
Gyre Therapeutics president sells $45,380 in stock - MSN
Gyre therapeutics president Ma Songjiang sells $45,434 in stock By Investing.com - Investing.com Nigeria
Gyre Therapeutics president Ma Songjiang sells shares totaling $50,020 By Investing.com - Investing.com Australia
Gyre Therapeutics president Ma Songjiang sells shares totaling $50,020 - MSN
Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells 2,000 Shares of Stock - MarketBeat
Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock - Armenian Reporter
Gyre therapeutics president Ma Songjiang sells $48,029 in stock - MSN
Gyre therapeutics president Ma Songjiang sells $48,029 in stock By Investing.com - Investing.com Canada
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 14.4% in January - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $22,360.00 in Stock - MarketBeat
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gyre Therapeutics Inc Stock (GYRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ma Songjiang | President |
Mar 10 '25 |
Sale |
10.14 |
2,000 |
20,280 |
2,839,260 |
| Ma Songjiang | President |
Mar 05 '25 |
Sale |
10.98 |
2,000 |
21,960 |
2,845,260 |
| Ma Songjiang | President |
Mar 06 '25 |
Sale |
10.80 |
2,000 |
21,600 |
2,843,260 |
| Ma Songjiang | President |
Mar 03 '25 |
Sale |
11.23 |
2,000 |
22,460 |
2,849,260 |
| Ma Songjiang | President |
Mar 04 '25 |
Sale |
10.86 |
2,000 |
21,720 |
2,847,260 |
| Ma Songjiang | President |
Feb 28 '25 |
Sale |
11.41 |
2,000 |
22,820 |
2,851,260 |
| Ma Songjiang | President |
Feb 27 '25 |
Sale |
11.33 |
2,000 |
22,660 |
2,853,260 |
| Ma Songjiang | President |
Feb 26 '25 |
Sale |
11.63 |
2,000 |
23,260 |
2,855,260 |
| Ma Songjiang | President |
Feb 25 '25 |
Sale |
11.37 |
2,000 |
22,740 |
2,857,260 |
| Ma Songjiang | President |
Feb 21 '25 |
Sale |
11.91 |
2,000 |
23,818 |
2,861,260 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):